Media Inquiries

If you are a credentialed member of the media, please submit a request via this link: Request For Comment | HHS.gov. If you are a scientist who has been contacted by a member of the media, please refer them to the link above.

News and Events

Fluorescent image showing the protein CSF-1R (green), microglia (red), and cell nuclei (blue) in a breast cancer brain metastasis model. Microglia cells near and inside the brain tumors are expressing the CSF-1R protein (yellow)

New Strategy Shows Promise Against Deadly Breast Cancer in the Brain

A new NIH study points to a promising strategy for treating aggressive breast cancer that spreads to the brain, a complication with few effective options. Learn how blocking a key brain cell survival pathway could open the door to future therapies.

Patient Testimonials

Read testimonials from patients and their families about their time at CCR.

Spatial heatmap of CD3+ T cells in small cell lung cancer (SCLC) tumors. Top: Notch1 gene inactive, “cold” SCLC with T cells located on the tumor periphery (immune-excluded). Bottom: Notch1 gene active, “hot” SCLC with abundant T cell tumor infiltration (immune-inflamed).

Activated gene elicits robust immune response in lung cancer

The activation of NOTCH1, a gene known to control cell differentiation and growth, stimulates a robust immune response in small cell lung cancer. Expression of this gene can also predict survival with immunotherapy.

Cells showing the biosensor used in this study to test the activity of APC/C

Study uncovers new details on pulsing enzyme activity during cell cycle

Enzymatic activity during the start of the cell cycle could be harnessed to inhibit cancer cell reproduction.

An illustration of immune cells with zeroes and ones, representing CIDE, a new, large-scale immuno-oncology data platform.

Cancer Immunology Data Engine uncovers secreted proteins with therapeutic potential

CCR researchers have developed a new tool that identifies secreted proteins associated with immunotherapy outcomes.

Graphic depiction of near-infrared photoimmunotherapy (NIR-PIT) targeted against ICAM-1 markers (small, blue, Y-shaped), causing cancer cell death and suppressed tumor growth (pink cluster, center).

CCR-developed cancer therapy shrinks tumors and boosts immune response

A targeted cancer therapy developed at CCR shows promise in its ability to target a common cancer cell marker, both shrinking tumors and producing a boosted immune response.

Clinical trial researching drug therapy for colorectal cancer

A clinical trial led by Tim F. Greten, M.D., Deputy Chief and Senior Investigator in the Thoracic and GI Malignancies Branch, is researching a two-drug therapy for adults with metastatic colorectal cancer.

A graphic depiction of the dimethoxyphenyl cyanoacrylamide (DiMe) chemical warhead facilitating reversible binding of drug to its molecular target.

Synthesized chemical component helps cancer drugs remain stable in water

Researchers developed a new chemical component that can be attached to drug molecules to make them more stable in water without losing effectiveness. This innovation could improve the performance of some cancer treatments.

Clinical trial researching immunotherapy for mesothelioma

A clinical trial led by Raffit Hassan, M.D., Chief and Senior Investigator in the Thoracic and GI Malignancies Branch, is researching an immunotherapy treatment for adults with solid tumors, including mesothelioma.

Doctor with patient. Image credit: Canva

Clinical trial researching drug therapy for multiple myeloma

A clinical trial led by Elizabeth M. Hill, M.D., Assistant Research Physician in the Lymphoid Malignancies Branch, is researching a combination drug therapy for myeloid malignancies.

Combining bevacizumab with erlotinib shrinks tumors in patients with rare and aggressive kidney cancer

Seventy-two percent of patients with HLRCC-associated kidney cancers, for which there previously was no known drug treatment, responded to the therapy in a clinical trial.

Breadcrumb

News and Events